Latest News

28 April 2016

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2016.

Read more

13 April 2016

Shareholder Update April 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar® for 2,4-D

> DEPTM cabazitaxel shows superior performance

> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEPTM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand

> MOU for VivaGel® condom in China

> Half-year financial results

> Bio-Europe® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

 

5 April 2016

Starpharma to present at Bio-Europe conference

Starpharma today announced that it will present this week at the Bio-Europe® conference in Stockholm. At the conference Starpharma will also be conducting partnering discussions with pharmaceutical companies for VivaGel® BV, DEPTM and other parts of Starpharma’s portfolio.

Read more

4 April 2016

DEP cabazitaxel shows complete and sustained tumour regression in breast cancer model

Starpharma today announced further efficacy results of its most recent DEP™ candidate, DEP™ cabazitaxel, in a human breast cancer model. These data will be presented along with an overview of Starpharma’s DEP™ platform at the BioEurope Spring 2016 conference in Stockholm later this week.

Read more

In the media

9 March 2016

AAP: Starpharma licenses VivaGel BV in Aust, NZ

"Starpharma is letting Aspen Pharmacare Australia market and distribute its Vivagel BV treatment in Australia and New Zealand for an undisclosed sum. Aspen will market and distribute the treatment for bacterial vaginosis, that's due to be launched in 2016, to clinicians and pharmacies. In return, Starpharma will receive royalties on net sales.

Starpharma still holds the commercialisation rights in the rest of the world."

Go to the article (external link)

17 December 2015

The Age: Starpharma set for condom sales in China

"Starpharma has signed a memorandum of understanding with a Chinese company to make and sell its VivaGel-coated condom in China...The Chinese company is a major supplier of condoms to the Chinese government's Birth Control Department and Disease Prevention Department. The so-called government market in China requires about three billion condoms each year for birth control and disease prevention."

Go to the article (external link)

17 November 2015

The Australian: Cancer trial results prove good medicine for biotech's stocks

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

24 September 2015

The Australian: Starpharma wins EU approval for VivaGel

The Australian reports that "Starpharma has been granted approval to market its VivaGel BV in the European Union's 28 member countries, where more than 260 million women live. The lubricant treats bacterial vaginosis (BV), the most common vaginal infection experienced by women around the world".

Go to the article (external link)

Shareholder Updates

13 April 2016

Shareholder Update April 2016

In this issue:

> Message from the CEO

> Adama licenses Priostar® for 2,4-D

> DEPTM cabazitaxel shows superior performance

> Starpharma's Targeted DEPTM conjugates - compelling results in an area of high interest

> AstraZeneca selects second DEPTM candidate

> Starpharma long standing collaborator ranked 4th in the world

> Starpharma signs licence with Aspen for commercialisation of VivaGel® BV in Australia and New Zealand

> MOU for VivaGel® condom in China

> Half-year financial results

> Bio-Europe® conference

Download: Shareholder Update April 2016 (pdf file, 1MB)

 

29 October 2015

Shareholder Update October 2015

In this Issue:

› EU marketing approval granted for VivaGel® BV
› Multi-product DEP® license with AstraZeneca
› VivaGel® BV: Symptomatic Relief and Treatment of BV/Prevention of recurrence
› VivaGel® condom
› Phase 1 DEP® docetaxel trial update                                                                                    

› Agrochemicals
› Starpharma in the News
› Starpharma full year financial results      

› Presentations and conferences

Download: Shareholder Update October 2015 (pdf file, 994kb)

Sign up to receive news here

© Starpharma Holdings Limited 2016